Founded in 2002 and headed by Daniel Tassé, DBV Technology is a biotech specializing in the development of innovative treatments for allergic diseases, particularly food allergies. Their objective? To offer safe, effective and practical solutions to the unmet needs of these patients. Here's a look at this company, valued at €322 million.
About DBV Technology
DBV Technology's revolutionary approach is based on its exclusive Viaskin® technology, which harnesses the benefits of epicutaneous immunotherapy, otherwise known as EPIT™. This innovative technology enables the precise and controlled delivery of drugs through the skin, offering a promising alternative to traditional treatments.
Its flagship product, Viaskin Peanut, is designed to treat peanut allergies in children. This unique medical device uses a patch to gradually release small quantities of peanut antigens, enabling safe, gradual desensitization to the allergens.
To guarantee the quality and reliability of their treatment, rigorous clinical trials are carried out in collaboration with world-renowned experts and regulatory bodies to obtain the necessary authorizations to market our products.
Growth encourages new projects
According to their financial results for the first quarter of 2023, the company reported some key performances during this period. Cash and cash equivalents totaled $192.3 million at March 31, 2023, compared with $209.2 million at December 31, 2022, representing a net decrease of $16.9 million.
As a pioneer in the field, the biotech intends to continue exploring the vast possibilities of this new class of immunotherapy, particularly for the treatment of inflammatory and autoimmune diseases that affect many patients.
DBV Technology: key information
Sales figures
2.19M in March 2023
Valuation
Estimated at 322M euros
Employees
85 employees by 2021
Scalability
With roots in France and a strong American and Australian presence, their ambition is global.
Objective
" At DBV Technology, we are aware of the positive impact we can have on the lives of millions of people. We are proud to contribute to the advancement of medical knowledge and to push back the limits of treatments for allergic diseases .
